Bml 259, CDK5, p25 kinase inhibitor

Get basic and detailed information about product. Buying link available


Catalog numberSIH-435-25MG
NameBml 259, CDK5, p25 kinase inhibitor
Size25 mg
Go to shop


Stock availabilitIn StockIn Stock
CAS number267654-00-2
DescriptionCDK5, p25 kinase inhibitor
Molecular weight260,4 g/mol
Primary research fieldsCell Signaling, Cancer, Apoptosis, Cancer Growth Inhibitors, Tyrosine Kinase Inhibitors
Other nameN-(5-Isopropylthiazol-2-yl)phenylacetamide
Product categorySmall Molecules
Product typeInhibitor
Chemical formulaC14H16N2OS
Purity pourcentage≥98% (TLC)
Soluble inSoluble in DMSO (30 mg/ml), dimethyl formamide (30 mg/ml) or 100% ethanol (0.25 mg/ml)
Physical appearanceWhite solid
Storage recommendations-20ºC
Shipping recommendationsShipped Ambient
Safety informationClassification: Not a hazardous substance or mixture. Safety Phrases: S22 - Do not breathe dust. S24/25 - Avoid contact with skin and eyes. S36/37/39 - Wear suitable protective clothing, gloves and eye/face protection.
PubChem number16760027
Scientific contextBml 259 is a potent inhibitor of Cdk5/p25. It also inhibits Cdk2/cyclin E.
Bibliography1. Kaźmierczak A., Czapski G.A., Adamczyk A., Gajkowska B., & Strosznajder J.B. (2011) Neurochem. Int. 58(2): 206–214.
Release date1-Oct-2014
PubMed numberRefer to PubMed
Tested applicationsTo be tested
Tested reactivityTo be tested
Representative figure legendChemical structure of BML 259 (SIH-435), a CDK5/p25 kinase inhibitor. CAS #: 267654-00-2. Molecular Formula: C14H16N2OS. Molecular Weight: 260.4 g/mol. Chemical structure of BML 259, a CDK5/p25 kinase inhibitor (SIH-435). CAS # 267654-00-2. Molecular Formula: C14H16N2OS.
Warning informationNon-hazardous
Country of productionCanada
Total weight (kg)0.25
Net weight (g)0.025
Additional descriptionTissue, pathway, proteinase, peptidase, protease ,acrosin, lipoprotein, activator, caspase, trypsin, papain, esterase inhibitors are proteins or receptor ligands or receptor antagonists that bind to an enzyme receptor and decreases its activity. Since blocking an enzyme's activity can kill a pathogen or correct a metabolic imbalance, many drugs are enzyme inhibitors. Not all receptor antagonist that bind to enzymes are inhibitors; enzyme activator ligands or agonists bind to enzymes and increase their enzymatic activity, while enzyme substrates bind and are converted to products in the normal catalytic cycle of the enzyme.